Hepatitis/MASH

Combination fast-tracked for approval to treat chronic HCV GT1 infection in end-stage renal disease patients on hemodialysis.

The FDA has granted 2 breakthrough therapy designations to grazoprevir/elbasvir.

HIV patients need to have undetectable viral load to undergo procedure.

Completion rates remain lower than rates reported in clinical trials.

Specialty drugs comprise 28% of total drug costs from just 1% of claims.

Medication would require no refrigeration and cost less than $1 per dose to manufacture.

Advances in treatment for chronic hepatitis C virus have been breaking news in the last few years.

Procedure allows acute liver failure patients to receive a transplant before their condition worsens.

Bristol-Myers Squibb is also clinically testing the potential of daclatasvir-based regimens in patients co-infected with HIV.

Patients with bile acid synthesis and peroxisomal disorders will soon have access to the first FDA-approved treatment option.

The agency is slated to review the new drug application within a 6-month timeframe.

Historical comparison shows advantage in virologic response for patients with genotype 1 hepatitis C.

New drugs help prevent needless HCV-related deaths.

Interferon-free, all-oral drug regimens result in high rates of sustained virologic response for patients co-infected with hepatitis C virus and HIV.

Many patients with non-alcoholic fatty liver disease also have low vitamin D levels.

This continuing education activity is supported by educational grants from Bristol-Myers Squibb and Gilead Sciences, Inc.

Viekira Pak is an all-oral regimen that has been approved by the FDA for the treatment of genotype 1 chronic hepatitis C virus infection.

Patients with hepatitis C benefit from a collaborative approach that involves specialty pharmacists and other care providers working with patients to promote patient engagement, adherence to therapy, and management of comorbidities.

In 2014, the FDA approved notable new therapies for the treatment of cancer, bleeding disorders, inflammatory conditions, cystic fibrosis, pulmonary fibrosis, HIV, hepatitis C, multiple sclerosis, angioedema, and other conditions.

As costly new specialty medications come to market, the role of the payer in controlling formularies is becoming increasingly apparent.

Genomic sequencing reveals effect of hepatitis on genetic mutations in tumors.

A recent study has identified how chronic hepatitis infection can pave the way to liver cancer.

Kidneys transplanted from infant who died days after birth.

Popularity of new treatments lead to shrinking demand for Merck's Victrelis.

Study warns there is no testing to support a net clinical benefit.